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This is an impressionistic and, therefore, undoubt- 
edly subjective view of one immunologist on what 
seem to him the most interesting developments in the 
broad realm of immunology in the last ten years. 
Even to mention exclusively the titles of all those 
studies which deserve comment here would take up 
more than all the space allotted. I must thus start by 
pleading with all those friends and colleagues whose 
interesting work is not mentioned here to bear with 
me. 
The progress of immunology on the molecular 
level has been enormous, and it is not an exaggeration 
to state that the basic structure of antibody has been 
essentially formulated and solved within this decade. 
This success was symbolized in the joint award of the 
Nobel prize in Medicine and Physiology for 1972 to 
Rodney Porter [l] and Gerald Edelman [2] . On the 
antigen side, we have reached a much better under- 
standing of the molecular basis of antigenicity (and of 
other immunological phenomena) largely due to the 
use of precisely designed immunogens. The synthetic 
approach has also been instrumental in the recent 
developments concerned with the genetic control of 
immune response. 
Lately we have begun to understand immunology 
at a cellular level. Certain crucial questions are still a 
matter of deep controversy, and the molecular ap- 
proach to cellular immunological phenomena has not 
been yet used too extensively. 
1. The antibody story 
Papain cleavage of immunoglobulin G (IgG) [3] 
resulted in two Fab fragments, possessing the sites 
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binding the antigen, and one Fc fragment (easily crys- 
tallizable), possessing several other biological proper- 
ties such as the capacity to fur complement and to 
bind to cells. On the other hand, Edelman [4] show- 
ed that IgG is a multichain structure. This led to the 
four chain - two H (heavy) and two L (light) - 
model of IgG (5) (fig. 1). This model immediately 
provided the molecular basis for the genetic markers 
of immunoglobulins known as allotypes [6,7]. It also 
became apparent at an early stage that light and 
heavy chains are present in all classes, and thus that 
all immunoglobulins have fundamentally the same 
structure [8]. 
Antibodies are very heterogeneous, but homoge- 
neous immuglobulins with antibody activity have 
been described and characterized in detail in the last 
decade. They were first of all identified among the 
paraproteins of patients with Waldenstrom’s macro- 
globulinemia and multiple myeloma. A Waldenstrom 
macroglobulin was shown to be an antibody of the 
IgM class directed against human IgG [9] . Human 
and mouse myeloma proteins, mostly of, the IgA 
class, were described possessing specificities as dis- 
parate as for the dinitrophenyl group and phosphoryl- 
choline [lo-121 . Their homogeneity led to a better 
understanding of structure and specificity than had 
been possible with heterogeneous antibodies. Homo- 
geneous antibodies have also been obtained experi- 
mentally. Thus, antibodies with specificity directed 
to streptococcal [ 131 and pneumococcal [ 141 poly- 
saccharides were found to be monoclonal. Repeated 
pasages of a very small number of cells also caused 
production of antibodies of very limited heterogene- 
ity [ 151, and so did antibody production by micro- 
cultures vitro [ 161. 
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Fig. 1. The structure of rabbit IgG. The rather complex arrangement of inter- and intrachain disulfide bonds in the heavy chain is 
shown. From Porter [I]. 
That antibodies of different specificities have dis- 
tinctive amino acid compositions [ 171, and that anti- 
body fragments [ 18,191 or entire molecules [20] 
could be completely unfolded reversibly, showed that 
antibody specificity was encoded in the amino acid 
sequence exclusively. The elucidation of the first 
amino acid sequences of the light chain [21,22] led 
to the conclusion that these chains are made of a 
variable (V) and a constant(C) portion, and thus that 
two genes code for each immunoglobulin light chain 
[23] . Similarly, the heavy chain of IgG (y chain) is 
composed of one variable and, in this case, three con- 
stant regions [24,25]. These studies culminated in 
the elucidation of the complete amino acid sequence 
of an IgG molecule [26], followed in the last year by 
the complete amino acid sequence of the pentameric 
IgM molecule [27] . 
The progress in the research of the antibody mole- 
cule has been reflected in several symposia [28-321, 
review articles [33-361 and in the volume published 
on the occasion of the First International Congress of 
Immunology [37]. One may find there in detail the 
convincing case made for the two extreme types of 
theories of antibody formation: germ line theories, 
which assume that all the information, i.e. antibody 
genes, may pre-exist in the germ line; and somatic 
theories, which assume that antibody diversity is 
generated during somatic differentiation (mutation or 
recombination) (for literature see, e.g., Williamson 
]381). 
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Singer and Thorpe [38a] and Edelman and his 
colleagues [2] suggested that the IgG molecule is 
folded in a series of compact domains, each formed 
by separate V homology regions or C homology re- 
gions (fig. 2). In such an arrangement, each domain is 
stabilized by a single intrachain disulfide bond and is 
linked to neighboring domains by less tightly folded 
stretches of the polypeptide chains. Do changes occur 
within the antibody molecule upon reaction with 
antigen or hapten? And if so, are they limited to the 
combining site region? Many techniques failed to 
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Fig. 2. The domain hypothesis. Diagrammatic arrangement of 
domains in the free IgG molecule is shown. The arrow refers 
to a dyad axis of symmetry. Homology regions that consti- 
tute each domain are indicated: Vb and VII are domains 
made up of variable homology regions; CL, c1.11, cH2 and 
CD3 are domains made up of constant homology regions. 
Within each of these groups, domains are assumed to have 
similar threedimensional structures, and each is assumed to 
contribute to an active site. The V domain sites contribute to 
antigen recognition functions and the C domain sites to ef- 
fector functions. From Edelman [ 21. 
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detect such changes, while others suggested changes 
within the combining site [39,39a]. Metzger con- 
cluded that no convincing evidence is at hand which 
demonstrates that reactions at the combining sites of 
an antibody produce defined conformational changes 
elsewhere in the molecule [39] . Differences in the 
circular dichroism spectra of anti-pneumococcal anti- 
bodies with a specific hexasaccharide [40] could be 
interpreted as due either to conformational changes 
in the combining site of the antibody or to a change 
in the environment of chromophores within the com- 
bining site. Tumerman et al. [41] concluded that 
flexibility of an antibody decreases upon reaction 
with hapten. Liberti et al. [42] assumed gross con- 
formational changes within the antibody to explain 
the change in its tritium exchange properties upon 
reaction with a synthetic macromolecular antigen. 
Reaction of antibodies with a tetra-D&nine hapten 
led to a large volume contraction, due to a change in 
conformation upon interaction [43]. 
Estimation of the size and nature of the combining 
sites has been reported for several antibodies, includ- 
ing those directed against oligosaccharides [44] and 
peptides [45,46]. A ‘dynamic mapping’ of the com- 
bining site of a myeloma protein with anti-dinitro- 
phenyl activity was obtained through kinetic studies 
using relaxation spectrometry [47] . The capacity to 
bind the antigen specifically is obviously confined to 
the variable domains of the molecule. So are the idio- 
types [48], or the individual antigenic specificities of 
immunoglobulins [49,50]. The notion of idiotypy of 
antibodies was first described in 1963 [51]. 
Considerable progress in the characterization of 
the active sites of antibodies was achieved by covalent 
affinity labeling, introduced by Singer [52,53]. Upon 
inspection of the amino acid sequences of the variable 
regions of heavy and light chains of immunoglobulin 
molecules, it became apparent that the positions at 
which variation occurs are dispersed throughout the 
variable regions. Certain portions showed a remark- 
able high degree of variability relative to the back- 
ground [54] . Three hypervariable regions were found 
in the light chains [55,55a]. Affinity-labelling techni- 
ques using different reagents have labelled residues in 
each hypervariable region, and labelled residues have 
never been found far from the hypervariable region 
[56-591 . The use of affinity labeling reagents with 
varied distances between the hapten and the ‘hook’ 
[60] , with two ‘hooks’ in the same molecule, for 
cross-linking [61] , as well as the use of photoaffinity 
labeling [62,63] , contributed importantly to our 
knowledge of the antibody combining site. 
Active fragments of antibodies, containing the VH, 
C, 1, V, and CL domains, have been obtained with 
papain [ 1,3], pepsin [64] and other proteolytic en- 
zymes, as well as by limited chemical cleavage with 
cyanogen bromide [65] . The only successful attempt 
to obtain a much smaller fully active antibody frag- 
ment has been the isolation of a peptic digestion 
product of an IgA mouse myeloma protein [66] . This 
fragment, named Fv, is formed from the amino ter- 
minal half of Fab, i.e. it is composed exclusively of 
VH and VL. 
Beside the immunoglobulins of the G and M class 
(IgG, IgM), our knowledge has progressed much on 
the IgA class, prominent in secretion [67]. Most ex- 
perimentally-induced mouse myeloma proteins are of 
this class [68] . The different classes share the same 
light chains, but differ in the heavy chains, which are 
Fig. 3. Electron micrograph of a single mouse IgM selected 
from a micrograph by Parkhouse et al. [ 761. Details of pre- 
paration are given in Parkhouse et al. [ 761. 
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Fig. 4. Photograph of the electron density map of the Fab’ fragment of McPC603 protein at 4.5 A resolution. The contours were 
drawn at equal but arbitrary intervals. Only positive contours above the first are shown. The upper half of the molecule (V) is 
identified with the variable region and the lower half (C) with the constant region of the fragment. The 2-(5’acetoxymercury-2’- 
thienyl)ethylphosphorylcholine difference peaks in the region believed to be the combining site are enclosed in a heavy dotted 
line and arrowed. From Padlan et al. [89]. 
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characteristic of the class. One of the most interesting 
observations in this connection is the discovery of a 
new chain, denoted J, which is present only in the 
polymeric IgM and IgA [69] . Two new classes of 
immunoglobulins have been discovered in recent 
years: IgD [70,71] , and IgE. Reaginic antibodies 
belong to the latter class [72] . 
During the last decade we have seen for the first 
time electron microscopic pictures of IgG [73], IgM 
[73-761 and IgA [77] molecules. An IgM molecule 
is illustrated in fig. 3. Electron micrographs have been 
also obtained of complexes between antibodies and 
antigens (e.g. [75]) or bifunctional haptens [77,78]. 
Ultimately, of course,.the real ‘seeing’ is through an 
X-ray crystallographic study of immunoglobulin 
molecules, and their active sites. Poljak et al. [79] 
first investigated an Fc fragment. An intact human 
IgG myeloma protein has been analyzed at 6 A reso- 
lution [80]. More recently, the structure of a light 
chain dimer (BenceJones protein) at 3.5 A resolution 
has been reported [81]. 
Most recently, the structure of the Fab’ fragment 
of a human myeloma IgG was determined by X-ray 
crystallographic analysis at 2.8 A resolution [82] . No 
a-helical conformation can be seen in the structure. 
The overall dimensions of the Fab’ molecule are 
80 X 50 X 40 A. Each of the four homology subunits 
can be enclosed in a parallelepiped of 40 X 2.5 X 25 A. 
A centrally located cleft divides the molecule into 
two structural domains, the variable and constant 
moieties. The structural subunits CL and C,l inter- 
act over a wider area and are more tightly packed 
than the VL and V, subunits. All four subunits 
are strikingly similar in their three-dimensional 
folding, as expected from the homology of their 
amino acid sequences and in agreement with the 
proposal of gene duplication as a mechanism of origin 
of immunoglbbulin genes. However, although the VL 
and VH subunits share the basic ‘immunoglobulin- 
fold’ of the CL and C, 1 subunits, they include an 
additional length of polypeptide chain in the form of 
a loop not present in the constant homology regions. 
The r@ions of hypervariable sequences of both L and 
H chains occur at one end of the molecule and are 
fully exposed to the solvent. There is no cavity in this 
region (probably the ‘active’ site), only a shallow 
groove. Although the structurally related L and H 
chains are clearly complementary, it appears that the 
H-chain exposes a larger area at the ‘active’ site [82] . 
In order to obtain reliable information about the 
combining site of antibody it is necessary to possess 
crystals with and without the hapten. This has been 
accomplished for the anti-dinitrophenyl mouse IgA 
myeloma protein [83], and led the way to the re- 
cently reported structure, at 4.5 A resolution, of a 
phosphorylcholine-binding Fab (papain-produced) 
fragment of McPC603 mouse myeloma immunoglob- 
ulin [84]. The electron density can be divided into 
four distinct globular regions which are interpreted 
to correspond to the four domains in the molecule 
(fig. 4). The hapten-binding site lies between two 
domains near one end of the molecule. 
2. Molecular basis of antigenicity 
Following the classical studies of Landsteiner 
[85] , great progress has been made in the investiga- 
tion of antigenic specificity, making largely use of 
haptens [46;86,87] . A useful distinction has been 
made between the notions of immunogenicity (i.e., 
capacity to trigger an immune response, independent- 
ly of its specificity) and antigenic specificity [88,89] . 
With the progress in the determination of struc- 
tures of proteins and nucleic acids, it is not surprising 
that great advances have been made in the elucidation 
of their immunochemical properties [90,91]. Where- 
as most fibrillar and all denatured globular proteins 
exhibit exclusively ‘sequential’ antigenic deter- 
minants, native globular proteins possess mainly or 
uniquely ‘conformation-dependent’ determinants 
[92,93 ] . Myoglobin [94,95] , egg white lysozyme 
[96,97] and staphylococcal nuclease [98] are’among 
the proteins analyzed most thoroughly from this 
point of view. A nice illustration of the sequential 
versus conformation-dependent determinants comes 
from a study showing complete lack of immuno- 
logical cross-reaction between the native hen egg 
white lysozyme and bovine lactalbumin systems, but 
very good cross-reaction between these two proteins, 
possessing a large extent of amino acid homology, 
after they were denatured [99]. The use of enzymes 
as antigens rather than other proteins, offers the 
advantage that they possess biologic activity that 
resides in a limited area of the molecule, and anti- 
bodies specific towards this or related regions may 
have an effect on the catalytic activity [ 1001. 
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A better understanding of the molecular basis of 
antigenicity, and of manifold immunological phe- 
nomena, became possible due to the use of synthetic 
antigens [93,99,101-1031 . The synthetic approach 
offers the advantage that, once the immunogenicity 
of one synthetic material has been unequivocally 
demonstrated, many analogues may be prepared and 
tested. If the antigen design is known, it is possible, 
through a study of compounds showing only limited 
variations in their chemical formulae, to arrive at 
conclusions concerning the role of various structural 
features in their antigenic function. Thus, homo- 
polymers of amino acids are very poor immunogens, 
and the immunogenicity increases with increased 
variations in composition. While macromolecular 
substances are more reliably immunogenic, low mole- 
cular weight compounds may be immunogenic pro- 
vided they have the right composition [ 1041. The 
presence of electrical charges on a macromolecule is 
not a minimum requirement for it to be immunogenic 
[93], but when the antigen is charged an inverse re- 
lationship persists between the net electrical charge 
on the immunogen and that on the antibodies it 
provokes [ 1051. In order to elicit antibody, the im- 
munogenically important area must be readily ac- 
cessible and cannot be hidden in the interior of the 
molecule [93]. 
Synthetic antigens may be prepared, leading to 
antibodies of almost any specificity desired, such as 
‘classical’ haptens, sugars, nucleosides, pyridoxal, 
folic acid and methotrexate, a phytoestrogen, ferro- 
cene, the glycolipid cytolipin H (for literature, see 
ref. [93] ), as well as brain lipids [ 1061, angiotensin 
[ 1071, bradykinin [ 1081, glucagon [ 1091, triiodo- 
thyronine [ 1 lo] , morphine [ 11 l] and prostaglandin 
A [ 1121. The size and nature of peptidic sequential 
determinants has been analyzed in detail by 
Schechter [ 1131. 
Cross-reactive antibodies may induce profound 
conformational changes in the antigen. Thus, anti- 
apomyoglobin antibodies give a white precipitate 
with myoglobin, the heme being extruded during the 
reaction [ 1141. As another illustration may serve the 
dramatic increase in the enzymatic activity of an 
almost inactive /3-galactosidase mutant upon reaction 
with antibodies against P-galactosidase from wild-type 
E. coli [ 1151. The conversion of a not yet helical 
small polymer of Tyr-Ala-Glu into a-helical shape 
s90 
upon reaction with antibodies against a higher mole- 
cular weight polymer of the same sequence, which is 
helical under physiological conditions, was followed 
by circular dichroic methods, thus showing an in- 
duced fit upon the reaction between the active sites 
of two biologically relevant macromolecules [ 1161. 
An acidic synthetic copolymer was shown to possess 
determinants whose conformation depends on reac- 
tion with calcium ions [ 1171. 
Synthetic antigens have been described capable of 
provoking antibodies cross-reacting with a bacterial 
cell wall [ 1181 , with the basic protein of the myelin 
sheath (such polymers may suppress the experimental 
disease, allergic encephalomyelitis, ref. [119,120]) as 
well as with collagen [ 1211 . In the latter case the 
cross-reaction is due to the similarity in three-dimen- 
sional structure. The synthesis of a portion of hen egg 
white lysozyme, denoted ‘loop’, followed by its 
chemical attachment to a branched amino acid 
polymer, yielded a synthetic immunogen which 
provoked antibodies reacting with lysozyme through 
a unique, conformation-dependent region [ 1221. All 
the conformational studies, as well as other studies 
[ 1031, lead to the inevitable conclusion that an anti- 
genie determinant is recognized while the immuno- 
genic macromolecule is still intact. 
The feasibility of preparing synthetic antigens that 
can provide antibodies against complex protein deter- 
minants conceptually opens the road to the vaccines 
of the future [ 1231. With polysaccharides ome suc- 
cess has already been achieved. An artificial colitose- 
containing antigen stimulated antibodies against cer- 
tain pathogenic Gram-negative bacteria [ 1241 . More 
recently, an artificial antigen containing 2-O-acetyl- 
abequose was described [ 1251. Antibodies made 
against it agglutinate certain strains of Salmondla. In 
another case, a synthetic antigen was built containing 
the presumed receptor site of wheat-germ agglutinin 
([ 1261, see also [ 1271). The antibodies cross-reacted 
with the receptor sites on tumor-cell surfaces. Mice 
immunized against this antigen rejected five times as 
many transplanted myeloma tumor cells as are reject- 
ed by otherwise identically treated control mice. The 
antigen acted, therefore, as a ‘chemical vaccine 
against tumor progression’. 
Synthetic antigens have also been helpful, i.e., in 
investigations of antigen metabolism [ 1281, delayed 
hypersensitivity [ 1291, immunological tolerance 
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(e.g., [ 130-132]), antigenic competition [ 1331 and 
the genetic control of immune response [ 134,135] . 
3. From molecule to cells 
Immunocytes are cells involved in the immune 
process, i.e. in the triggering and maintenance of the 
immune response. They are mainly long-lived small 
mononuclear lymphocytes [ 1361 . Macrophages also 
play a role in most instances of immune triggering 
[ 137-1391. The selection theory [ 1401 in its clonal 
form [ 1411 demands that cells will have receptors for 
antigen before they encounter antigens. Such re- 
ceptors were found on immunocyte membranes, and 
they were found to be immunoglobulins [ 142-1441. 
In accordance with the theory, a very low but signifi- 
cant percentage of immunocytes in a normal cell 
population is able to bind specifically the antigen 
[145-1471. Cells have been fractionated on the basis 
of their receptor for antigen [148-1501. Methods 
were developed for elegant detection of antibody- 
producing cells [ 15 I] and for antibody synthesis in 
vitro [ 152,153] , including primary antibody forma- 
tion in vitro to defined synthetic antigens [ 1541 . It 
was proven beyond doubt that one cell makes anti- 
bodies of only one antigenic specificity (e.g., 
[155,156]). In agreement with this observation, it 
was found recently that one cell possesses antigen 
receptors of only one specificity [ 1571 . 
The thymus is an organ of paramount importance 
for the development of immunity [ 158-1601. The 
immunocompetent lymphocytes can be divided into 
two general types on the basis of functional differ- 
ences: T cells - small lymphocytes that have adapted 
to certain specific immune functions by virtue of 
some as yet undefmed influence of the thymus 
(thymus-derived); and B cells - small lymphocytes 
that have not been directly influenced by the thymus 
and which are the progenitors of mature antibody- 
producing cells (see, e.g. [161]). Cooperation be- 
tween T and B cells has been demonstrated for 
humoral antibody responses ([ 162,163] , for later 
literature, see, e.g. [164]). Antigen receptors seem to 
be present on both types of cells. It is unequivocally 
established that the receptors on B cells are of im- 
munoglobulin nature (for review, see [39,165]). On 
the other hand, there is considerable controversy 
concerning the receptor on the T cell, many reports 
denying its putative immunoglobulin structure (for 
review, see [147,161]). 
In his brilliant critique of the state of immuno- 
logical art in 1967 [ 1661 , Jerne has discussed, i.e., 
the ‘receptor puzzle’. It is clear that the immunogenic 
carrier is more than an inert macromolecule to which 
an antigenic determinant is attached, and that it is 
crucial in defining both the elicitation and the struc- 
ture of antibodies [ 1671. Moreover, it has become 
clear that in most cases an immune response neces- 
sitates the cooperation of two cells whose immuno- 
logical specificity is different, even though both are 
capable of reacting with the same immunogen 
[166,168-1711 . This bicellular interaction leading, 
e.g., to an anti-hapten antibody, is indeed between 
thymes and bone marrow-derived cells (e.g., [ 1721). 
The influence of T cells in the cellular events of in- 
duction of antibody formation and tolerance has 
been summarized recently [ 1731. Some antigens are 
‘thymus-independent’, most probably because they 
possess repeating antigenic determinants and are 
slowly metabolizable (see [ 164,173] ). From a mole- 
cular standpoint it is of interest that collagen is a 
thymus-independent antigen, whereas the gelatin 
derived from it is thymus-dependent [ 1741. The thy- 
mic function may be replaced by either specific (e.g. 
[ 175- 1771) or non-specific [ 1781 soluble factors. 
These seem to differ from the previously described 
thymic hormones [ 179,180] . 
The two types of functionally different lympho- 
cytes may be distinguished by virtue of their surface 
antigenic markers (for review, see [181]). It was 
shown recently that antibodies reacting with lympho- 
cyte surface immunoglobulin molecules induce these 
to gather over one pole of the cell (to ‘cap’), sugges- 
ting a possible mechanism for lymphocyte triggering 
by antigen [ 1821. Many studies have appeared in the 
last year, extending the initial ‘patching’ and ‘capp- 
ing’ phenomena to other immunocyte markers, which 
are protein components floating in the lipid bilayer of 
a cell membrane (e.g., [ 1871). A suggestion has been 
made that there are receptors on lymphocytes also 
for autoantigens, and that it is the autologous serum 
which inhibits self-recognition [ 1841. 
& -Microglobulin is a low-molecular-weight protein 
constituent of lymphocyte membranes, whose amino 
acid sequence has been recently determined. It shows 
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a striking homology with certain parts of immuno- 
globulin chains [ 185,186] , suggesting for it a possible 
recognition function. Indeed, it seems that there is a 
relation between the &-microglobulin, some serologi- 
tally defined transplantation antigens [ 1871 , and 
recognition units on the T lymphocyte surface, 
supporting the concept that phenotypic products of 
the HL-A chromosomal region may function in re- 
cognitive processes [ 188,189] . 
Progress has been made also in the cell-free biosyn- 
thesis of immunoglobulins. Light and heavy chains 
are made on separate polysomes [ 190,191] . The 
biosynthesis of the carbohydrate portion of immuno- 
globulin chains and their relation to secretion have 
also been studied [ 1921. Study of the assembly of 
immunoglobulin M showed that intracellularly it 
exists solely in the form of 7 S subunits [ 1931. Ex- 
citing studies are under way on the messenger RNA 
for light [ 194-1971 and heavy [ 1981 chains. An 
active antibody has been synthesized in a wheat-germ 
cell-free system [ 1991 . 
4. Genetic control of immune response 
Even though immunity is not inherited, the capa- 
city to respond immunologically well or poorly ap- 
pears to be under genetic control [134,135,200]. The 
immune response of guinea pigs to hapten conjugates 
of poly-L-lysine is predicated upon the presence of an 
autosomal dominant gene which is referred to as the 
PLL gene [201] . This finding was followed by the 
demonstration of a determinant-specific genetic con- 
trol of antibody formation to a series of branched 
synthetic polypeptides in inbred strains of mice 
[202] , and by the detection of genetic control at the 
level of antibody specificity [203] . These studies 
were performed with synthetic antigens, most proba- 
bly because their restricted antigenic heterogeneity 
allowed for clear-cut results. Indeed, when very small 
doses of complex proteins were used for immuniza- 
tion, genetic differences in response were also detect- 
ed [204,205]. Direct proof for the hypothesis that 
the use of complex antigens may blur genetic control 
of their various unique determinants came from a 
study of the antigenic determinants of lysozyme 
[206]. 
McDevitt and Chinitz have shown that the immune 
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responses of inbred mice to a related series of three 
branched synthetic polypeptide antigens studied pre- 
viously [202] are closely correlated with the geno- 
type for the major histocompatibility (H-2) locus 
[207]. A similar linkage has been observed between 
the major histocompatibility locus of inbred strain 2 
guinea pigs and the PLL gene [208] . Tens of antigens 
have been by now described, that show clear genetic 
differences in inbred strains of various animal species, 
and in many cases these genetic controls are linked to 
the major histocompatibility locus of the species 
[209-2111. It has also been reported that specific 
reaginic antibody response is linked to the HL-A 
haplotype in humans [212,213]. 
Genetic control of specific immune responses is 
now a well-established phenomenon [214] , and many 
responses have been mapped precisely within the H-2 
region (e.g., [210]). Thus, e.g., genes for antibody 
response to IgG and IgA are in independent loci 
[215] . As the capacity to respond to certain antigens 
is determined by genes, and some of these lie within 
the same chromosomal region as the genes for histo- 
compatibility antigens, it seems possible that the 
products of these genes may themselves be histocom- 
patibility antigens, and that they serve as recognition 
sites on certain cells (possibly T cells) of the immune 
system [209,214] . Some indirect evidence supporting 
the hypothesis that the histocompatibility-linked 
immune response genes are expressed always on the T 
cell has been reported recently [214,216,217]. A 
cellular analysis of several immune response gene 
systems [ 135,218-2211 led Sela and his colleagues 
to the conclusion that the genetic defect in the 
immune response is reflected in thymocytes when the 
poor response is at the carrier level, whereas it is ex- 
pressed in the bone marrow population when the low 
responsiveness i strictly at the determinant level 
[103]. 
5. Immunology as a tool 
Immunological techniques have been used for a 
long time in other disciplines, but the last decade has 
seen an exponential increase in the use of immunolo- 
gical tools in literally tens of other fields, for detec- 
tion of various compounds, for visualization by 
means of immunofluorescent and radioactive techni- 
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ques, for isolation of antigens and haptens. It includes 
studies such as X-ray diffraction of muscle labelled 
with antibody to C-protein [222], and blocking of 
the electrophysiological response of the electroplax 
to carbamylcholine by means of rabbit antiserum 
against purified Electrophorus electricus acetylcho- 
line receptor [223] . I shall mention here explicitly 
only their diagnostic value. 
Antibodies have been used widely for sensitive 
detection and quantitation of antigens and haptens. 
These may include small molecules such as drugs and 
vitamins and macromolecules such as proteins (e.g. 
hormones, carcinoembryonic antigens) and nucleic 
acids. The most widely used technique is the radio- 
immunoassay [224-2261. More recently, both viro- 
immunoassay (making use of chemically modified 
bacteriophage) [227-2291 and enzymoimmunoassay 
[230-232a] have been efficiently employed. A modi- 
fication of the radioimmunoassay extends its use to 
detection and quantitation of reaginic antibodies 
[233], and thus opens the road to efficient in vitro 
diagnosis of allergic diseases. 
6. Concluding remarks 
This summary statement dealt only with anti- 
bodies, antigens, cellular cooperation and genetic 
control of immune response, and even in these fields 
the list of inevitable omissions is long. Whole fields of 
immunology, such as autoimmune diseases, immune 
disorders in man, manipulation of the immune re- 
sponse [37,234] , transplantation [235], complement 
[37,236,237] and tumor immunology [37], have not 
been mentioned at all. 
As for Jerne’s ‘Waiting for the End’ [ 1661, it 
seems that indeed the end - the solution - is in sight 
for the antibody molecule. The stage is now set, and 
the game can start with the cells. 
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